Payment overview · 2025
General Payments
$206.70
12 reported records · 5 companies
Healthcare provider profile · identity verified
David D Rotman, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · ROBINSON, IL · NPI 1730204405
Verified facts
What the public records show
CMS Open Payments records show David D Rotman, M.D. received $206.70 in general payments during 2025 across 12 reported records.
Lilly USA, LLC accounted for 42.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Mounjaro by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $88.67 | 42.9% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $67.50 | 32.7% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $20.25 | 9.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.49 | 7.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.79 | 7.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $206.70 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $126.49 | 7 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $29.68 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $29.68 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $20.25 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 70 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
70 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
70 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 448 | 71 |
| Levothyroxine Sodium | Levothyroxine Sodium | 388 | 70 |
| Allopurinol | Allopurinol | 297 | 45 |
| Furosemide | Furosemide | 270 | 48 |
| Potassium Chloride | Potassium Chloride | 269 | 50 |
| Amlodipine Besylate | Amlodipine Besylate | 218 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 214 | 40 |
| Atorvastatin Calcium | Atorvastatin Calcium | 209 | 42 |
| Eliquis | Apixaban | 207 | 22 |
| Famotidine | Famotidine | 197 | 31 |
| Glipizide Er | Glipizide | 192 | 28 |
| Metformin Hcl | Metformin Hcl | 176 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 162 | 23 |
| Gabapentin | Gabapentin | 156 | 29 |
| Montelukast Sodium | Montelukast Sodium | 152 | 26 |
| Simvastatin | Simvastatin | 152 | 28 |
| Pantoprazole Sodium | Pantoprazole Sodium | 149 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 137 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 135 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 134 | 23 |
| Trazodone Hcl | Trazodone Hcl | 119 | 18 |
| Verapamil Er | Verapamil Hcl | 109 | 14 |
| Omeprazole | Omeprazole | 106 | 17 |
| Sertraline Hcl | Sertraline Hcl | 105 | 21 |
| Lorazepam | Lorazepam | 104 | 20 |
| Carvedilol | Carvedilol | 101 | 16 |
| Buspirone Hcl | Buspirone Hcl | 98 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 92 | 19 |
| Sucralfate | Sucralfate | 87 | 18 |
| Januvia | Sitagliptin Phosphate | 84 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 81 | 16 |
| Bumetanide | Bumetanide | 74 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 71 | 39 |
| Jardiance | Empagliflozin | 70 | suppressed |
| Chlorthalidone | Chlorthalidone | 68 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 61 | 20 |
| Lisinopril | Lisinopril | 60 | 16 |
| Propranolol Hcl Er | Propranolol Hcl | 60 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 57 | 18 |
| Spironolactone | Spironolactone | 54 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 53 | 53 |
| Finasteride | Finasteride | 52 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 51 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 50 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 49 | 22 |
| Amitriptyline Hcl | Amitriptyline Hcl | 49 | 11 |
| Dexamethasone | Dexamethasone | 49 | 33 |
| Nifedipine Er | Nifedipine | 49 | 14 |
| Alprazolam | Alprazolam | 47 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 46 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 44 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 44 | suppressed |
| Prednisone | Prednisone | 44 | 31 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 42 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 42 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 42 | suppressed |
| Ezetimibe | Ezetimibe | 41 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 41 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 40 | 25 |
| Xarelto | Rivaroxaban | 40 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 39 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 37 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | suppressed |
| Acarbose | Acarbose | 34 | suppressed |
| Digoxin | Digoxin | 34 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 32 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Fluconazole | Fluconazole | 30 | 12 |
| Labetalol Hcl | Labetalol Hcl | 29 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 29 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 28 | 25 |
| Zafirlukast | Zafirlukast | 28 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 27 | suppressed |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Meloxicam | Meloxicam | 25 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 25 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Baclofen | Baclofen | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 24 | suppressed |
| Mounjaro | Tirzepatide | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 21 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 21 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | suppressed |
| Glimepiride | Glimepiride | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 12 |
| Azithromycin | Azithromycin | 18 | 13 |
| Diltiazem Hcl | Diltiazem Hcl | 18 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 17 | 17 |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Sotalol | Sotalol Hcl | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Budesonide | Budesonide | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Methimazole | Methimazole | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Pentoxifylline | Pentoxifylline | 15 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Cefdinir | Cefdinir | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 12 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 11 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $206.70 · 12 records | Lilly USA, LLC | BREZTRI, JARDIANCE, MOUNJARO, VRAYLAR, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error